Compounders Research Compare

Rein Therapeutics Inc.(RNTX)

Biotechnology · Austin, TX

$0.830.00 (0.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Rein Therapeutics Inc.

Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

Austin, TX

10 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: James Brian Windsor

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T21:18:08.395Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:18:08.395Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 23,063,679
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 8,542,000
TTM operating EBITDA · period ending 2026-06-30: -20,134,000

FMP input reference: 6f5be79ac0e7715def3f298c248b41853c7a510be646acbaec4ce361b11b20d4

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RNTX EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

RNTX Competitors' EV/EBITDA Ratio

Rein Therapeutics Inc.

Current

Market Cap

$23.06M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TherapeuticsMD, Inc.

Market Cap

$23.38M

EV/EBITDA Ratio

N/A

TTM Avg

0.53x

3Y Avg

0.52x

5Y Avg

0.52x

LeonaBio, Inc.

Market Cap

$22.68M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Modular Medical, Inc.

Market Cap

$22.25M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aytu BioPharma, Inc.

Market Cap

$22.00M

EV/EBITDA Ratio

N/A

TTM Avg

6.88x

3Y Avg

5.95x

5Y Avg

5.95x

Kyntra Bio, Inc.

Market Cap

$24.13M

EV/EBITDA Ratio

N/A

TTM Avg

70.33x

3Y Avg

70.33x

5Y Avg

70.33x

Atossa Therapeutics, Inc.

Market Cap

$24.44M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InspireMD, Inc.

Market Cap

$24.60M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABVC BioPharma, Inc.

Market Cap

$25.22M

EV/EBITDA Ratio

N/A

TTM Avg

11456.84x

3Y Avg

11456.84x

5Y Avg

11456.84x

NextCure, Inc.

Market Cap

$20.53M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Rein Therapeutics Inc. (RNTX)	$23.06M	N/A	N/A	N/A	N/A
TherapeuticsMD, Inc. (TXMD)vs ›	$23.38M	N/A	0.53x	0.52x	0.52x
LeonaBio, Inc. (LONA)vs ›	$22.68M	N/A	N/A	N/A	N/A
Modular Medical, Inc. (MODD)vs ›	$22.25M	N/A	N/A	N/A	N/A
Aytu BioPharma, Inc. (AYTU)vs ›	$22.00M	N/A	6.88x	5.95x	5.95x
Kyntra Bio, Inc. (KYNB)vs ›	$24.13M	N/A	70.33x	70.33x	70.33x
Atossa Therapeutics, Inc. (ATOS)vs ›	$24.44M	N/A	N/A	N/A	N/A
InspireMD, Inc. (NSPR)vs ›	$24.60M	N/A	N/A	N/A	N/A
ABVC BioPharma, Inc. (ABVC)vs ›	$25.22M	N/A	11456.84x	11456.84x	11456.84x
NextCure, Inc. (NXTC)vs ›	$20.53M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics